Saudi FDA allows more time to address deficiencies in drug submissions
This article was originally published in SRA
Executive Summary
The Saudi Food and Drug Authority has issued a revised guideline that provides pharmaceutical companies with more time to respond to deficiencies in their submissions concerning new marketing authorisations, renewals and variations to existing products1,2.